Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $592,499.70 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne Whitfield sold 7,397 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the sale, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tarsus Pharmaceuticals Trading Up 5.1%

Shares of NASDAQ:TARS opened at $81.40 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -40.30 and a beta of 0.74. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a 50 day moving average price of $75.13 and a 200 day moving average price of $58.18.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The company had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allianz Asset Management GmbH acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $227,000. TFG Asset Management GP Ltd raised its holdings in shares of Tarsus Pharmaceuticals by 40.1% during the second quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after acquiring an additional 71,530 shares in the last quarter. Lisanti Capital Growth LLC boosted its position in Tarsus Pharmaceuticals by 7.6% during the second quarter. Lisanti Capital Growth LLC now owns 75,525 shares of the company’s stock valued at $3,060,000 after purchasing an additional 5,345 shares during the last quarter. Strs Ohio purchased a new position in Tarsus Pharmaceuticals in the first quarter valued at about $288,000. Finally, Jump Financial LLC increased its position in Tarsus Pharmaceuticals by 385.9% in the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on TARS shares. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, HC Wainwright lifted their price objective on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.86.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.